Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19
01 Juin 2022 - 12:00PM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing patented Microcyn® technology-based
stabilized hypochlorous acid (HOCl) products for a wide range of
applications, including wound, eye, oral and nasal care,
dermatological conditions and disinfectant use, and its partner,
the MicroSafe Group DMCC, are pleased to announce that Nanocyn®
hospital grade disinfectant has been added to the list of COVID-19
disinfectants maintained by the U.S. Environmental Protection
Agency’s List N.
Nanocyn hospital-grade disinfectant was approved by the EPA for
use as a disinfectant in April 2022 as the Company has previously
announced. The addition to the COVID-19 disinfectant list
represents an extension of this approval.
The EPA expects products on List N to kill all strains and
variants of the coronavirus SARS-CoV-2 (COVID-19) when used
according to the label directions. Before products can legally make
claims that they can kill a particular pathogen such as SARS-CoV-2,
the claim must be authorized by the EPA based on rigorous testing
and strict review of the scientific data. The inclusion of Nanocyn
on the EPA’s List N represents a major achievement for Nanocyn and
Microcyn Technology.
In addition, Nanocyn, also known as MicroSafe® in Europe and
West Asia, recently achieved European Standard (EN) 17272 for
Airborne Room Disinfection. Achieving this EN Standard shows that
Nanocyn/MicroSafe is capable of completely disinfecting a room
contaminated with bacteria and viruses by fumigating the airspace
when following the directions of use. This automated fumigation
process of room disinfection enables healthcare and other
facilities in Europe to more efficiently disinfect entire rooms and
other surfaces.
“The MicroSafe Group is very pleased with Nanocyn being included
on the EPA’s List N for disinfectants to be used against SARS-CoV-2
(COVID-19),” said Safwan Abdallah, COO of the MicroSafe Group.
“Furthermore, Nanocyn’s contact time is 30 seconds for viruses.
This coupled with its extraordinarily low toxicity profile as
categorized by the EPA (lowest Category IV per 40 CFR 156.62) makes
Nanocyn an important tool for curbing the spread of infection.”
“We are excited to see regulators in the U.S. and E.U. approve
additional uses of Nanocyn and our Microcyn Technology,” said Amy
Trombly, CEO of Sonoma. “Our own MicrocynRX® Skin & Wound care
family of products has been used successfully in many varied
healthcare settings for years to eradicate bacteria, viruses and
fungi. We are eager to expand the role Microcyn Technology plays in
improving the health and safety of people around the world.”
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care, and
dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 54 countries worldwide and the company
actively seeks new distribution partners. The company has offices
in Woodstock, Georgia, and Boulder, Colorado, as well as
manufacturing operations in Latin America. European marketing and
sales are headquartered in Roermond, Netherlands. More information
can be found at www.sonomapharma.com. For partnership
opportunities, please contact busdev@sonomapharma.com.
About MicroSafe Group
The MicroSafe Group has operations internationally with its head
office in Dubai, United Arab Emirates. With regional offices in the
Middle East, as well as MicroSafe Care Australia and Canada,
MicroSafe Group is providing innovative solutions to a wide range
of industries and healthcare providers. The MicroSafe Group
promotes only products it believes will truly revolutionize
healthcare – products that will enrich the lives of patients and
healthcare professionals all over the world. Interested
distributors for Europe, West Asia and North Africa may contact
Safwan Abdallah, COO of MicroSafe Group at info@microsafecare.com.
For Australia please contact MicroSafe Australia’s Managing
Director Matt Seifert, at info@microsafe.com.au. More information
can be found at www.microsafe.com and www.microsafe.com.au.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “expect,” “promise,” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks
resulting from the global COVID-19 pandemic, that regulatory
clinical and guideline developments may change, scientific data may
not be sufficient to meet regulatory standards or receipt of
required regulatory clearances or approvals, clinical results may
not be replicated in actual patient settings, protection offered by
the company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the company’s products will not be as large as expected,
the company’s products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to meet the
company’s cash needs, fund further development and clinical
studies, as well as uncertainties relative to varying product
formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, and other
risks detailed from time to time in the company’s filings with the
Securities and Exchange Commission. The company disclaims any
obligation to update these forward-looking statements, except as
required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or
registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220601005494/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024